ATM immunohistochemistry as an effective screening method for POLE variants among endometrial carcinomas lacking mismatch repair deficiency and p53 abnormalities.

However, identification of polymerase-ε (POLE) variants remains reliant on DNA sequencing, which limits broader implementation.

Given the strong prognostic value of pathogenic POLE mutations and the established efficacy of immunohistochemistry (immunohistochemistry) for detecting mismatch repair (mismatch repair) deficiency and p53 abnormalities, there is a clear need for immunohistochemistry-based screening strategies to identify patients likely to carry POLE variants and prioritize them for confirmatory sequencing.